According to filings with the U.S. Securities and Exchange Commission, I Peace is raising up to $16,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About I Peace
I Peace is a cell and gene therapy CDMO specializing in iPSC-derived cell products. We provide cGMP cells/iPSCs and contract manufacturing services for medical use globally. The company was founded in 2015 by Koji Tanabe, a graduate of Professor Shinya Yamanakas lab at Kyoto University and the second author of the paper that reported the worlds first successful establishment of human iPS cells. Tanabe, who has been involved in iPS cell research since the beginning of its development, is committed to making iPS cells accessible to all people through I Peace. I Peaces unique technology enables the parallel production of multiple donor-derived iPS cells without contamination concerns and makes it possible to provide a large number of iPS cells at a reasonable cost. I Peace supports drug discovery and cell therapy development through the use of the iPS cell and other cell products that meet PMDA and FDA standards as high-quality cell products for pharmaceutical and cell therapy companies, and also promotes the production of iPS cells for individuals so that each and every person in the world can prepare for the future by possessing his or her own iPS cells. In addition to supporting pharmaceutical and cell therapy companies so that cell therapy will be within the reach of patients as soon as possible, I Peace aims to spread regenerative cell therapy as soon as possible by establishing iPS cell banking services for individuals.

To learn more about I Peace, visit http://ipeace.com/
I Peace Linkedin Page: https://www.linkedin.com/company/i-peace-inc./

Contact:
Koji Tanabe, Chief Executive Officer
650-380-2387
https://www.linkedin.com/in/koji-tanabe-b73932297/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.